explain the market cap, page-13

Thank you, that is the first responsible and clear response I have had on this thread and I appreciate your thoughts. My understanding is that the highest dose of OPT302 in combination with lucentis provided a statistically significant improvement in letters from 10.8 to 14.2 which is reported as 30% improvement over Lucentis. Is that sufficient to partner - I don't know, but I agree it's good. Probably better than my first analysis so again I thank you. This trial had some interesting secondary data and of course it was found to be safe. All good. The global market for wAMD is probably worth $10B per annum (ish) and there are at least a dozen players in the field and two drugs on the market in Australia. Lucentis and Eylea are on the PBS at $41 non-concession per treatment so it's likely they will be the first port of call for treatment as a solo treatment. Assuming success OPT302 may be the third? Fourth? Fifth? agent on the market. The adage is always first in class or best in class - so we are hoping for best in class as a combination therapy. I try and figure risk, market share, royalty rate and return on investment which I have done. But thank you again, your correction of my perception is most appreciated.